Ibuprofen News and Research

RSS

Ibuprofen is a drug used to treat fever, swelling, pain, and redness by preventing the body from making a substance that causes inflammation. It is a type of nonsteroidal anti-inflammatory drug (NSAID). Ibuprofen is a propionic acid derivate and nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic effects. Ibuprofen inhibits the activity of cyclo-oxygenase I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. This leads to decreased prostaglandin synthesis, by prostaglandin synthase, the main physiologic effect of ibuprofen. Ibuprofen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation.

Ibuprofen may cause heart attacks - full disclosure of all data - including industry safety data - is essential

Speaking at the annual European conference of rheumatology, EULAR 2005, in Vienna, Austria, today (Friday 10 June 2005), Dr. Gurkirpal Singh, from Stanford University, USA, said:

10 Jun 2005

Commonly used painkillers for treating inflammation may increase the risk of heart attack

Patients should not stop taking the drugs involved - non-steroidal anti-inflammatory drugs (NSAIDS) - but further investigation into these treatments is needed, say the authors.

9 Jun 2005

New study linking pain relievers and breast cancer fails to convince experts

Research in recent years has consistently linked the use of aspirin and other anti-inflammatory pain relievers with a lower risk of colon cancer, but findings about the drugs' effect on breast-cancer risk have been very mixed with some studies suggesting that the pain relievers protect against breast cancer, while others have found no link.

1 Jun 2005

Ibuprofen use is associated with an increased risk of breast cancer

Ibuprofen use is associated with an increased risk of breast cancer, and long-term daily use of aspirin is associated with an increased risk of estrogen receptor/progesterone receptor (ER/PR)-negative breast cancer, according to a new study in the June 1 issue of the Journal of the National Cancer Institute.

30 May 2005

Latest patterns of medication use in the U.S.

In 2004, 82 percent of adults and more than 50 percent of children took at least one prescription, over-the-counter (OTC), or herbal/natural medication in any given week, Boston University researchers revealed recently.

30 May 2005

Paracetamol linked to asthma and reduced lung function

Scientists now suspect that regular use of the painkiller paracetamol, is linked with higher rates of asthma and chronic obstructive pulmonary disease (COPD) and reduced lung function.

3 May 2005

NSAIDs okay for tonsillectomy, new study finds

When children have their tonsils removed, nonsteroidal anti-inflammatory drugs can be used for pain relief with no significant increase in bleeding and with less nausea and vomiting, according to a systematic review of current evidence.

19 Apr 2005

Study predicted cardiovascular risk of Cox-2 inhibitors

Amid the recent controversy and confusion over serious side effects from pain medications, a new UCLA and Veterans Affairs Greater Los Angeles Healthcare System study demonstrates that for arthritis sufferers at high risk for gastrointestinal problems who traditionally may have used a drug like Vioxx, the most cost-effective and safest treatment is actually a common painkiller combined with an acid-reducing drug.

11 Apr 2005

Pfizer separately agrees to suspend sales of Bextra due to FDA evaluation of risks of rare but serious skin reactions

Pfizer said today it will work with the U.S. Food and Drug Administration (FDA) to add expanded risk information in the Celebrex label following an FDA decision announced this morning to require boxed warnings of potential cardiovascular risk for all COX-2 pain relievers and all NSAIDs, including older non-specific drugs such as ibuprofen and naproxen.

7 Apr 2005

Pfizer withdraws Bextra from market

Despite an expert panel stating last month that the three COX-2 drugs Vioxx, Bextra and Celebrex were safe enough to be marketed, the U.S. Food and Drug Administration (FDA) has this week told drug manufacturer Pfizer to remove the drug Bextra from the market and a statement by Pfizer confirms that the European Union regulators have done the same.

7 Apr 2005

Paracetamol effective for chronic pain and arthritis

A research team from University of Queensland has just published the results of a small study into the effectiveness of medications for chronic pain.

27 Jan 2005

Painful surgical adhesions may be preventable by taking the COX-2 inhibitor Celebrex

Adhesions – bands of scar tissue that bind together two internal body surfaces – develop in 55 percent to more than 90 percent of patients undergoing surgery, depending on the type of operation. They are part of normal healing, but when surfaces fuse together that shouldn't, serious pain and complications can result.

26 Jan 2005

Vioxx could have caused 140000 excess cases of coronary heart disease in the USA since 1999

The arthritis drug Vioxx could have caused an estimated 88 000–140 000 excess cases of serious coronary heart disease in the USA since its launch in 1999, concludes a study published online by The Lancet.

24 Jan 2005

Are NSAIDS enough for cancer pain?

Non-steroidal anti-inflammatory drugs (NSAIDs) are effective in managing cancer pain with few side effects, according to a new review of a number of studies.

24 Jan 2005

Chronic users NSAIDs have greater risk of bleeding and visible damage to their small intestine

According to a study published today in the American Gastroenterological Association (AGA) journal Clinical Gastroenterology and Hepatology, chronic users of non-steroidal anti-inflammatory drugs (NSAIDs) have an increased risk of bleeding and visible damage to their small intestine.

4 Jan 2005

Arthritis drug caution advised by New Zealand experts

An expert New Zealand committee reviewing the safety of a group of arthritis drugs called COX-2 inhibitors has reinforced UK advice cautioning against their routine use where safe and effective alternatives are available.

21 Dec 2004

Advice for patients who have been taking Celebrex or Bextra

The recent announcement that Celebrex, a popular pain drug in the same family as Vioxx, has been found to pose an increased risk of heart problems is bound to leave many pain patients stunned, confused and worried.

20 Dec 2004

Greater risk of heart attack associated with Vioxx than Celebrex

In the first epidemiological study designed and executed specifically to determine the heart-attack risk associated with COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex), researchers at the University of Pennsylvania School of Medicine found a greater risk of heart attack associated with Vioxx than Celebrex, although neither of the two drugs showed a statistically significant elevated risk of heart attack relative to people who did not use the drugs.

8 Dec 2004

New insight into anticoagulation therapies

Anticoagulation therapies, or treatments that reduce the amount of clotting factors in the blood, are quite common and used for a variety of reasons.

6 Dec 2004

Indoprofen may lead to new treatments for spinal muscular atrophy

A drug withdrawn from pharmacy shelves over 20 years ago may point the way to a new treatment for spinal muscular atrophy, or SMA, a muscle-wasting and often life-threatening childhood disease.

29 Nov 2004